Sinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024

MT Newswires Live

Jan 20, 2025

Sinopharm Group's (HKG:1099) subsidiary China National Accord Medicines (SHE:000028, SHE:200028) expects to log a net profit attributable to shareholders between 561 million yuan and 760 million yuan for 2024.

The expected net profit is 52.48% to 64.92% lower than 1.60 billion yuan recorded for 2023, a Sunday Hong Kong bourse filing said.

China National Accord Medicines also expects to see basic earnings between 1.01 yuan per share and 1.37 yuan per share for the reporting period, compared with 2.87 yuan per share recorded for the prior year.

The decrease in expected attributable net profit was attributed to impairment of intangible assets arising from goodwill and other assets including receivables and inventories, and allocation of certain acquisition consideration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2504942905"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2504942905\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2504942905?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-20 14:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504942905","market":"nz","top_or_hot":-1,"title":"Sinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024","media":"MT Newswires Live","content":"<html><body><p> Sinopharm Group's (HKG:1099) subsidiary China National Accord Medicines (SHE:000028, SHE:200028) expects to log a net profit attributable to shareholders between 561 million yuan and 760 million yuan for 2024.</p><p>The expected net profit is 52.48% to 64.92% lower than 1.60 billion yuan recorded for 2023, a Sunday Hong Kong bourse filing said.</p><p>China National Accord Medicines also expects to see basic earnings between 1.01 yuan per share and 1.37 yuan per share for the reporting period, compared with 2.87 yuan per share recorded for the prior year.</p><p>The decrease in expected attributable net profit was attributed to impairment of intangible assets arising from goodwill and other assets including receivables and inventories, and allocation of certain acquisition consideration.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-20 14:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sinopharm Group's (HKG:1099) subsidiary China National Accord Medicines (SHE:000028, SHE:200028) expects to log a net profit attributable to shareholders between 561 million yuan and 760 million yuan for 2024.</p><p>The expected net profit is 52.48% to 64.92% lower than 1.60 billion yuan recorded for 2023, a Sunday Hong Kong bourse filing said.</p><p>China National Accord Medicines also expects to see basic earnings between 1.01 yuan per share and 1.37 yuan per share for the reporting period, compared with 2.87 yuan per share recorded for the prior year.</p><p>The decrease in expected attributable net profit was attributed to impairment of intangible assets arising from goodwill and other assets including receivables and inventories, and allocation of certain acquisition consideration.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0640798160.USD","symbol_name":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2504942905","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504942905","pubTimestamp":1737356231,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sinopharm Group's  subsidiary China National Accord Medicines  expects to log a net profit attributable to shareholders between 561 million yuan and 760 million yuan for 2024.The expected net profit is 52.48% to 64.92% lower than 1.60 billion yuan recorded for 2023, a Sunday Hong Kong bourse filing said.China National Accord Medicines also expects to see basic earnings between 1.01 yuan per share and 1.37 yuan per share for the reporting period, compared with 2.87 yuan per share recorded for the prior year.The decrease in expected attributable net profit was attributed to impairment of intangible assets arising from goodwill and other assets including receivables and inventories, and allocation of certain acquisition consideration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK1197":"保健护理产品经销商","01099":"国药控股","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1515":"抗疫概念","BK1500":"做空集合股"},"translate_title":"国药集团子公司预计2024年归属利润最多下降65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Group's (HKG:1099) subsidiary China National Accord Medicines (SHE:000028, SHE:200028) expects to log a net profit attributable to shareholders between 561 million yuan and 760 million yuan for 2024.The expected net profit is 52.48% to 64.92% lower than 1.60 billion yuan recorded for 2023, a Sunday Hong Kong bourse filing said.China National Accord Medicines also expects to see basic earnings between 1.01 yuan per share and 1.37 yuan per share for the reporting period, compared with 2.87 yuan per share recorded for the prior year.The decrease in expected attributable net profit was attributed to impairment of intangible assets arising from goodwill and other assets including receivables and inventories, and allocation of certain acquisition consideration.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}